Respiratory Infections

More transmissible variants are emerging quickly. An expert explains why it's expected, but concerning.

A discussion around the relatively shocking effect of the virus on infants, and what's needed in long-term assessment of the patient group.

From vaccine studies to reopening institutions, pooled testing may be a hugely beneficial tool.

The global health agency provided current insights and advisories into 4 different variants observed during COVID-19 this year.

The newly published data show no patient given the two-dose mRNA vaccine has yet to report a case of severe COVID-19.

A new multicenter study confirms earlier findings that the panel performs well against the more time-intensive quantitative bacterial culture.

Though regulatory authorization has not been granted, the company intends to vaccinate up to 50 million people prior to the Lunar New Year.

Though research is pending, the CEO used simple science to explain why the mRNA vaccine may still prevent from the UK variant.

A new case series report highlights the unique circumstances of infant illness associated with COVID-19.

New data suggests informed, practical pooled testing could improve both public health response and clinical assessment of the pandemic.

The VRBPAC voted 20-0 with 1 abstention to support the benefit-risk profile associated with mRNA-1273.

While the number of study participants was too small to extrapolate for the whole population, the authors said they were encouraged.

Influenza and pneumonia, though rare, occurred at roughly the same rate in both the high-dose and standard-dose vaccine groups.

A universal flu vaccine is also another step closer, according to researchers at Mount Sinai.

The updated vaccine efficacy and safety outcomes include 37,000-plus participants from the ongoing, multi-national trial.

Investigators identify gene expression which may explain the highly transmissible nature of the virus.

Previous studies with influenza in animals demonstrated antiviral efficacy was not species restricted.

Physicians are beginning to find key patterns which will aid public health in the future.

Cincinnati, Ohio-based Blue Water Vaccines is working on developing a vaccine that will permanently protect against current and future influenza strains.

COVID-19 is a dynamic disease which evolves as it disrupts host programs and rewires modules.

LabCorp, an early adopter with extensive geographic reach, will be the first lab offering the test in the United States.

Recent study may have implications for social and public health policies

New study may help contribute to COVID-19 research.

Patients with pervasive conditions are found to be more at risk for a severe case of COVID-19.